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Expression of the class IIa HDACs is frequently altered in different human
cancers. In mouse models these transcriptional repressors can trigger trans-
formation, acting as bona fide oncogenes. Whether class IIa HDACs also
exhibit transforming activities in human cells is currently unknown. We
infected primary human fibroblasts with retroviruses to investigate the
transforming activity of HDAC4 in cooperation with well-known onco-
genes. We have discovered that HDAC4 triple mutant (S246A, S467A,
S632A) (HDAC4-TM), a nuclear resident version of the deacetylase, trig-
gers TP53 stabilization and OIS (oncogene-induced senescence). Unlike
RAS, HDAC4-induced OIS was TP53-dependent and characterized by
rapid cell cycle arrest and accumulation of an unusual pattern of cH2AX-
positive foci. The inactivation of both TP53 and of the retinoblastoma
(pRb) tumor suppressors, as induced by the viral oncogenes large and
small T of SV40, triggers anchorage-independent growth in RAS, HDAC4-
TM and, to a lesser extent, in HDAC4-wild type (WT)-expressing cells.
Our results suggest an oncogenic function of class IIa HDACs in human
cells, and justify further efforts to discover and evaluate isoform-specific
inhibitors of these epigenetic regulators from a therapeutic perspective.
1. Introduction
The remodeling of transcriptional programs is a key
aspect of tumorigenic processes (Bradner et al., 2017).
Oncogenes and tumor suppressor genes can influence
transcription directly by acting as transcription factors
(TFs) or indirectly by supervising signaling pathways that
control the transcriptional machinery (Bradner et al.,
2017). Transcriptional remodeling requires epigenetic
changes and the involvement of chromatin modifiers
(Brien et al., 2016; Yang et al., 2012). Epigenetic plastic-
ity is emerging as an important hallmark of cancer. At
each step of tumor progression, from initiation to evolu-
tion, epigenetic plasticity is necessary to fuel new waves of
transcription (Koschmann et al., 2017).
Histone modifications contribute to chromatin
remodeling and to the epigenetic signature. Dysfunc-
tions in enzymes controlling these post-transcriptional
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modifications (PTMs) can affect the tumorigenic pro-
cess (Cheng et al., 2017a,b; Montero-Conde et al.,
2017). Both pro-tumorigenic and tumor-suppressive
activities have been reported for some epigenetic regu-
lators, which reflects the importance of the specific cel-
lular context (Beira et al., 2018; Chen et al., 2018;
Koschmann et al., 2017; Wang et al., 2017).
In addition to alterations in epigenetic regulators,
mutations in histones can trigger the tumorigenic pro-
cess. Oncogenic mutations in H3.3 genes encoding
K27M and G34R/V have been characterized in pedi-
atric high-grade gliomas (Fontebasso et al., 2014;
Khuong-Quang et al., 2012; Schwartzentruber et al.,
2012; Taylor et al., 2014).
Histone deacetylases (HDACs) are important erasers
of epigenetic marks. HDAC can be subdivided into five
subclasses (I, IIa, IIb, III and IV). Class IIa includes
four members (HDAC4/5/7/9) characterized by a
poor deacetylase activity, phosphorylation-dependent
nuclear/cytoplasmic shuttling and an extended amino-
terminal region devoted to TFs and co-repressor bind-
ing (Martin et al., 2007). The C-terminal deacetylase
domain is required to interact with the SMRT/N-CoR/
HDAC3 complex, which confers the KDAC activity
(Lahm et al., 2007). Important partners of class IIa
HDACs are members of the MEF2 (myocyte enhancer
factors) family of TFs (Clocchiatti et al., 2013a,b; Di
Giorgio and Brancolini, 2016). There is evidence from
several reports of the altered expression of class IIa in
human cancer (Barneda-Zahonero and Parra, 2012;
Clocchiatti et al., 2011). Furthermore, in vitro and
in vivo studies have proved the oncogenic role of
HDAC4 (Di Giorgio et al., 2013; Peruzzo et al., 2016),
HDAC7 (Di Giorgio et al., 2013; Lei et al., 2017; Rad
et al., 2010) and HDAC9 (Gil et al., 2016) in different
murine models. Since human cells behave differently
from rodent cells and, in general, require more genetic
alterations to acquire a neoplastic phenotype (Boehm
et al., 2005), whether these deacetylases can transform
human cells is currently unknown.
In vitro oncogenic transformation of normal cells
represents an invaluable model to prove tumor-
suppressive or oncogenic functions of a specific gene
(Funes et al., 2014). The robustness of the assay is cor-
roborated by the correlation between the in vitro trans-
forming activities of the tested genes and their
implications in human cancers (Boehm and Hahn,
2005; Boehm et al., 2005; Maya-Mendoza et al., 2015;
Seger et al., 2002). Moreover, these in vitro generated
transformed cells can provide alternatives to costly
mouse models, as well as genetically defined environ-
ments for testing anticancer therapies (Balani et al.,
2017). In this manuscript we investigated the ability of
HDAC4 to cooperate with well-known oncogenes to
transform human fibroblasts.
2. Materials and methods
2.1. Cell cultures and reagents
The BJ/TERT cells were cultured in Earle’s salts minimal
essential medium (EMEM) (Euroclone, Milan, Italy)
completed with nonessential amino acids (HyClone, Lit-
tle Chalfont, UK). Media were supplemented with 10%
FBS, L-glutamine (2 mM), penicillin (100 UmL1), and
streptomycin (100 lgmL1) (Lonza, Basel, Switzerland).
Cells expressing the inducible form of the transgenes
were grown in medium without phenol red. For S-phase
analysis, cells were grown for 3 h with 50 lM bromod-
eoxyuridine (BrdU, Sigma). Mouse anti-BrdU (Sigma,
St. Louis, MO, USA) was used as the primary antibody
in the immunofluorescent assays. Nuclei were stained
with Hoechst 33258 (Sigma).
2.2. Invasion and soft agar assays
For invasion assay, each well of the invasion chamber
(CLS3428, Corning, New York, NY, USA) was coated
with 200 lL of Matrigel matrix coating solution (Cul-
trex, Trevigen, Gaithersburg, MD USA). Next, a cell
suspension of 30 000 cells in 0.1% FBS-Dulbecco’s
modified Eagle’s medium (DMEM) was added. As
chemoattractant, 20% FBS-DMEM was added in each
lower chamber. As a control, 0.1% FBS-DMEM was
used to evaluate random invasion. For soft agar
assays, equal volumes of 1.2% agar and DMEM were
mixed to generate 0.6% base agar. A total of
0.8 9 105 cells were seeded in 0.3% top agar, followed
by incubation at 37 °C in humidified conditions. The
cells were grown for 21 days and visualized by MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] staining. Images were taken with a DN6000 Leica
microscope that allows the the number and the diameter
of the foci to be counted.
2.3. Plasmid construction, transfections,
retroviral infections
The pWZL/HDAC4-WT and mutants, pWZL-Neo/
E1A (1–143) and pBABE-Puro/myristoylated AKT1
(myr-AKT1)-expressing plasmids were previously
described (Astle et al., 2012; Deng et al., 2005; Di Gior-
gio et al., 2013). pCW-Puro/HDAC4 and H-RAS/
G12V plasmids were obtained by subcloning with a
PCR method, HDAC4 and H-RAS/G12V into the all-
in-one DOX-inducible pCW-Cas9 plasmid (#50661
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Addgene, Cambridge MA, USA). pMXPIE-Puro
HDAC4-WT/TM, H-RAS/G12V were obtained by sub-
cloning with a PCR method the ORF into the 4
hydroxy-tamoxifen (4-OHT)- inducible pMXPIE plas-
mid (Toledo et al., 2008). The plasmids used to silence
MEF2D and plasmids encoding for MEF2D-FLAG
and MEF2-Engrailed FLAG (MEF2-ENG) were previ-
ously described (Di Giorgio et al., 2015, 2017). For len-
tivirus-based knock-down, HEK-293T cells were
transfected with 1.8 lg of VSV-G, 5 lg of D8.9 and
8 lg of pLKO plasmids. After 36 h at 37 °C, virions
were collected and opportunely diluted in fresh medium.
Retroviral infections were performed as previously
described (Di Giorgio et al., 2017).
2.4. RNA extraction and quantitative qRT-PCR
Cells were lysed using Tri-Reagent (Molecular
Research Center, Cincinnati, OH USA). A total of
1 lg of total RNA was retrotranscribed using 100 U
of Moloney murine leukemia virus reverse transcrip-
tase (Invitrogen, Carlsbad, CA, USA). qRT-PCR anal-
yses were performed using Bio-Rad CFX96 and SYBR
green technology (Resnova, Roma, Italy). The data
were analyzed by a comparative threshold cycle using
the b2 microglobulin gene and hypoxanthine phospho-
ribosyltransferase 1 (HPRT) as normalizer genes. All
reactions were done in triplicate.
2.5. Antibodies
Antibodies used were against MEF2D (BD Bio-
science), H3K27ac (ab4729; Abcam, Cambridge, MA,
USA). H3K27me3 (ab195477, Abcam) HDAC4 (Par-
oni et al., 2004), cH2AX (9718, Cell Signalling, Lei-
den, The Netherlands), TP53 (DO-7; Dako, Santa
Clara, CA, USA), LT SV40 (sc-147, Santa Cruz),
Lamin B1 (ab16048, Abcam), p21 (CP74, Sigma),
RACK1 (sc-17754, Santa Cruz, Dallas, TX, USA),
GFP (Paroni et al., 2004).
2.6. Immunofluorescence and immunoblotting
Immunofluorescence and immunoblotting were per-
formed as previously described (Di Giorgio et al.,
2017). Briefly, cells were fixed with 3% paraformalde-
hyde and permeabilized with 0.1% Triton X-100. Sec-
ondary antibodies were conjugated to Alexa Fluor 488,
546 and 633 (Molecular Probes, Eugene, OR, USA).
Cells were imaged with a Leica confocal microscopy
(LSM) SP2 and SP8. After SDS/PAGE and
immunoblotting, cell lysates were incubated with pri-
mary antibodies. HPR-conjugated secondary antibodies
were from Sigma-Aldrich and blots were developed with
Super Signal West Dura (ThermoFisher Scientific,
Waltham, MA, USA).
2.7. SA-b-gal assay
For SA-b-gal assay, cells were fixed in a solution of 2%
formaldehyde/0.2% glutaraldehyde and stained with
staining solution: 40 mM citric acid/Na phosphate buf-
fer, 5 mM K4[Fe(CN)6]3H2O, 5 mM K3[Fe(CN)6],
150 mM sodium chloride, 2 mM magnesium chloride
and 1 mgmL1 X-gal (Debacq-Chainiaux et al., 2009).
Staining was performed for 16 h at 37 °C and cells were
imaged under bright-field microscope (Leica). To quan-
tify SA-b-gal activity, the percentage of positively
stained blue cells versus total cells were counted (300–
400 cells in total were counted per each round).
2.8. Matrigel plug assay
A total of 1600 cells were suspended in a Matrigel solu-
tion (20 lL 0.1% FBS-EMEM, 60 lL Matrigel) and
plated on coverslips in 35-mm tissue culture plates.
After 30 min of incubation at 37 °C, cells were fed with
EMEM–20% FBS. Following a 4-day incubation,
coverslips were fixed and processed for fluorescence
analysis.
2.9. Transcriptome profiling and data analysis
Total RNA was isolated using Direct-zol RNA mini prep
(Zymo Research). Preparation and hybridization of
cRNA samples were performed at Cogentech (Milan,
Italy, https://www.cogentech.it/). Labeled cRNAs were
hybridized on Affymetrix GeneChip Human Clariom S
arrays. Differentially expressed genes (DEGs) were
selected based on 1.5 cut-off in the fold changes. Analysis
was performed as previously described (Di Giorgio et al.,
2013; Picco et al., 2014). Gene set enrichment analysis
(GSEA) (Subramanian et al., 2005) and the MSigDB
database (http://software.broadinstitute.org/gsea/index.
jsp) (Liberzon et al., 2015) were used to investigate statis-
tical association between genes modulated by HDAC4-
TM or RAS and genes perturbed by other conditions.
2.10. Statistics
For experimental data, a Student t-test was used. A
P-value of 0.05 was chosen as the statistical limit of
significance. Unless otherwise indicated, data in the fig-
ures are arithmetic means and standard deviations
from at least three independent experiments: *P < 0.05,
**P < 0.01, ***P < 0.005.
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3. Results
3.1. Nuclear resident HDAC4 induces senescence
in human fibroblasts (BJ-TERT)
To explore the contribution of HDAC4 to the transfor-
mation process we used skin-derived BJ fibroblasts,
immortalized with the telomerase catalytic subunit
(TERT). Since HDAC4 is subjected to intense nuclear
export following phosphorylation-mediated 14-3-3
binding, we took advantage from a Ser/Ala mutated
version in the three 14-3-3 binding sites (HDAC4-TM).
This mutant exhibits stronger repressive activity and is
sufficient to transform NIH-3T3 murine fibroblasts (Di
Giorgio et al., 2013). Additional HDAC4 mutants
tested were a nuclear resident form lacking the MEF2-
binding site (HDAC4-TMDMEF2) and a mutant in the
nuclear export sequence (HDAC4-L1062A), which simi-
larly to the TM, accumulate in the nucleus (Fig. 1A) (Di
Giorgio et al., 2013).
All HDAC4 versions were expressed in BJ-TERT
fibroblasts after retroviral infections. We also used
well-known oncogenes such as RAS (H-RAS-G12V)
and AKT1 (myr-AKT1), for comparison. Expression
of the different transgenes was verified by immunoblot
(Fig. 1B).
Non-transformed human fibroblasts respond to the
introduction of oncogenes by activating OIS (Astle
et al., 2012; Kennedy et al., 2011; Serrano et al.,
1997). Hence, we evaluated the presence of cells posi-
tive for SA-b-galactosidase activity (Fig. 1C). After
selection, few cells were recovered when nuclear local-
ized forms of HDAC4 were expressed. The few cells
expressing HDAC4-TM were positive on SA-b-gal
staining, with a score comparable to RAS and AKT1
(Fig. 1D). Cells expressing two nuclear mutants of
HDAC4 such as L1062A (Paroni et al., 2004) and
TMDMEF2 (Di Giorgio et al., 2013) were only moder-
ately positive on SA-b-gal staining (Fig. 1D). Both
mutants accumulate into the nucleus with a rate com-
parable to HDAC4-TM but are less strongly bound to
chromatin (Paroni et al., 2007). SA-b-gal positivity
was not relevant in cells expressing HDAC4-WT
(which is largely cytoplasmic in BJ/TERT cells) or the
negative control GFP (Fig. 1D).
To characterize the massive induction of senescence, we
generated an estrogen receptor alpha (ER)-inducible ver-
sion of HDAC4-TM, HDAC4-WT and H-RAS/G12V.
HDAC4-TM was expressed less compared with the
wild type (Fig. 1E), possibly because of the protea-
some-dependent nuclear degradation of HDAC4 (Cer-
notta et al., 2011). Next, we analyzed cell proliferation
2 or 8 days after transgene induction (Fig. 1F).
HDAC4-TM triggered a rapid block in DNA synthesis.
By contrast, RAS initially enhanced cell proliferation;
only after 8 days of induction DNA synthesis was
blocked. When the presence of SA-b-gal-positive cells
was investigated, only the induction of HDAC4-TM
and RAS stimulated SA-b-gal activity (illustrated in
Fig. 1G and quantified in Fig. 1H). Finally, to corrob-
orate these data and to exclude a contribution of
tamoxifen to the process of senescence, we used a sec-
ond inducible system. The different transgenes were
efficiently induced by the doxycycline-inducible system
(Fig. 1I). The SA-b-gal staining confirmed that the
induction of HDAC4-TM triggers senescence with
rates comparable to RAS and AKT1 (Fig. 1J). In sum-
mary, nuclear resident HDAC4 can trigger senescence
in immortalized human fibroblasts. In contrast to
RAS, an early proliferative block characterizes
HDAC4-TM-induced senescence.
3.2. DNA damage in HDAC4-TM-induced
senescence
OIS in RAS-overexpressing cells is triggered by the
accumulation of unrepaired damaged DNA caused by
unscheduled DNA synthesis (Di Micco et al., 2006).
Fig. 1. The HDAC4 expression in human fibroblasts. (A) Schematic representation of the different HDAC4 versions used in this study.
Phosphorylated serine residues, binding sites for 14-3-3 proteins are indicated. (B) Immunoblot analysis using the indicated antibodies in BJ/
TERT expressing the indicated transgenes. Vimentin was used as loading control. (C) Normal human diploid fibroblasts (BJ) expressing the
telomerase catalytic subunit (TERT) infected with retrovirus expressing the indicated genes and stained for senescence-associated
b-galactosidase (SA-b-gal) marker. Scale bar: 50 lm. (D) Quantitative analysis of SA-b-gal positivity from experiments described in (C). Data
are expressed as means  SD, n = 3. Student t-test: *P < 0.05, ***P < 0.005. (E) Immunoblot analysis using the indicated antibodies in BJ/
TERT expressing the indicated transgenes following treatment with 4-OHT for 48 h. RACK1 was used as loading control. (F) Analysis of
cells synthesizing DNA, as scored after BrdU staining at the indicated times. Data are expressed as means  SD, n = 4. Student t-test:
**P < 0.01, ***P < 0.005. (G) BJ-TERT expressing the indicated transgenes after 8 days of induction were stained for SA-b-gal activity.
Scale bar: 50 lm. (H) Quantitative analysis of SA-b-gal positivity from experiments described in (G). Data are expressed as means  SD,
n = 4. ***P < 0.005. (I) Immunoblot analysis using the indicated antibodies in BJ/TERT expressing the indicated transgenes following
treatment with doxycycline for 48 h. Vimentin was used as loading control. (J) Quantitative analysis of SA-b-gal positivity in BJ-TERT cells
expressing doxycycline-inducible versions of the indicated transgenes after 8 days of induction. Data are expressed as means  SD, n = 3.
Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005.
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Hence, we compared by time course the kinetics of
accumulation of cH2AX-positive cells in cells
expressing HDAC4-TM/ER, HDAC4-WT/ER and
H-RAS-G12V/ER. As early as 2 days after transgene
induction, HDAC4-TM-expressing cells showed an
accumulation of DNA damage (Fig. 2A). In contrast,
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in RAS-expressing cells, DNA damage became consis-
tent only after 8 days of induction with tamoxifen
(Fig. 2B). A few cH2AX-positive cells were also
observed in the case of HDAC4-WT (Fig. 2B). When
immunofluorescence was analyzed in more detail, two
phenotypes appeared evident: (a) nuclei in TM- and
RAS-expressing cells were larger than in control and
HDAC4-WT cells; (b) nuclei of TM cells showed fewer
but bigger cH2AX-positive foci than did RAS cells
(Fig. 2C). Quantitative analysis confirmed this obser-
vation (Fig. 2D,E).
Next, we evaluated the epigenetic modifications
induced by the different transgenes. The global levels
of histone H3 lysine 27 acetylation (H3K27ac), a mar-
ker of open and transcriptional active chromatin, and
of H3K27me3, a marker of facultative heterochro-
matin, were evaluated after 2 and 8 days of transgene
induction. We also evaluated the levels of Lamin B1,
which is down-regulated during senescence (Freund
et al., 2012). Whereas H3K27ac and Lamin B1 showed
a similar behavior in TM and RAS cells, with a dra-
matic decrease at day 8 (Fig. 2F), the pattern of
H3K27me3 was different between the two senescence
responses. Only in RAS cells did a transient reduction
occur at day 2, as recently observed (Ito et al., 2018).
Senescent cells produce and release a range of
cytokines, chemokines and proteases in the extracellu-
lar environment: the senescence-associated secretory
phenotype (SASP) (Coppe et al., 2008). Hence, we
compared the kinetics of appearance of senescence and
SASP after HDAC4-TM or RAS induction by analyz-
ing the expression levels of SASP components (IL1B,
IL8 and CSF2) and those of the CDK inhibitors
CDKN1A and CDKN2A, key regulators of the senes-
cent response. QRT-PCR analysis proved that
HDAC4-TM anticipated the appearance of senescence
with respect to RAS (Fig. 2G) in terms of SASP and
CDKN2A induction. In RAS-expressing cells this
response was only evident after 8 days of induction.
3.3. HDAC4-induced senescence depends on TP53
activation
The induction of DNA damage in TM-expressing cells
prompted us to investigate the contribution of TP53.
Immunoblot analysis performed after 8 days of trans-
gene induction demonstrated a strong up-regulation of
TP53 levels in TM cells (Fig. 3A). To investigate the
contribution of TP53 in TM-induced senescence, we
generated BJ-TERT cells expressing TP53 mutant
R175H (Fig. 3B). This mutant is frequently found in
human cancers and acts as a dominant negative
(TP53DN) (Gualberto et al., 1998). The DN effect was
shown on the TP53-target genes DEC1 and GADD45A
(Fig. 3C). Subsequently, we generated BJ-TERT/TP53
cells expressing HDAC4-TM, RAS or GFP as control.
Immunoblot analysis confirmed the expression of the
different transgenes and showed that Lamin B1 was
not down-regulated in TM cells, thus suggesting the
escape from senescence (Fig. 3D). SA-b-gal activity
(Fig. 3E) and the relative quantitative analysis
(Fig. 3F) confirmed the failure of TM in triggering
senescence, once the TP53 response was blunted. In
contrast, in RAS-expressing cells, suppression of TP53
activities was not sufficient to block the occurrence of
senescence (Fig. 3E,F), as previously observed (Ser-
rano et al., 1997).
These experiments demonstrate that HDAC4-TM
triggers senescence, which is markedly different from
RAS, since it is characterized by: (a) an early prolifera-
tive block, (b) an early and peculiar induction of DNA
damage and (c) a strong TP53-dependency.
3.4. Down-regulation of MEF2 transcription is
sufficient to promote senescence
HDAC4 can interact with several proteins, among
which MEF2 TFs represent important partners (Cloc-
chiatti et al., 2013a). Since HDAC4-TM deleted in the
Fig. 2. HDAC4-induced senescence is characterized by DNA damage. (A) Quantitative analysis of the immunofluorescence staining for
cH2AX after 2 days of induction of the indicated transgenes in BJ-TERT cells. Data are expressed as means  SD, n = 4. Student t-test:
*P < 0.05, **P < 0.01, ***P < 0.005. (B) Quantitative analysis of the immunofluorescence staining for cH2AX after 8 days of induction of
the indicated transgenes in BJ-TERT cells. Data are expressed as means  SD, n = 4. Student t-test: **P < 0.01, ***P < 0.005. (C)
Immunofluorescence picture of cH2AX positivity after 8 days of induction of the indicated transgenes. Nuclei were stained with Hoechst
33342. Scale bar: 5 lm. (D) Quantitative analysis of nuclear dimension in BJ-TERT cells following 8 days of induction of the different
transgenes. Measures were obtained with IMAGEJ. At least 50 nuclei were scored for each condition. The means and the 1st and 3rd quartiles
are indicated. *P < 0.05, ***P < 0.005. (E) Percentage of cH2AX-positive cells with the indicated numbers of cH2AX foci in the nuclei of BJ-
TERT cells, after 8 days of expression of the indicated transgenes. (F) Immunoblot analysis using the indicated antibodies in BJ-TERT cells
expressing the different transgenes for 2 or 8 days. Actin was used as loading control. (G) mRNA expression levels of the indicated genes,
as measured by qRT-PCR in BJ/TERT cells expressing the different transgenes following treatment for the indicated days with 4-OHT. Data
are expressed as means  SD, n = 3. Student t-test: *P < 0.05, **P < 0.01.
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MEF2-binding region triggers senescence less potently
compared with HDAC4-TM (Fig. 1C), we hypothesized
that the induction of senescence could be partially due
to the repression of these TFs. To clarify this point, we
generated BJ-TERT cells expressing MEF2-ENG, a
repressive version of these TFs in which the C-terminal
MEF2 activation domain is substituted by the Engrailed
repressor domain (Arnold et al., 2007). Cells overex-
pressing MEF2D or HYGRO were used as controls
(Fig. 4A). Appearance of senescence was clearly
observed in BJ-TERT-MEF2/ENG cells but not in the
controls (Fig. 4B). To alternatively down-regulate the
expression of MEF2-target genes, we silenced the expres-
sion of MEF2D using a shRNA (Fig. 4C). MEF2D
downregulation triggered a senescence response, charac-
terized by a strong impairment in S-phase entry
(Fig. 4D) and the accumulation of SA-b-gal-positive
cells (Fig. 4E and quantitative analysis in Fig. 4F).
Finally, similarly to HDAC4-TM, senescence in
response to MEF2 transcriptional repression is TP53-
dependent. BJ-TERT-TP53DN cells expressing RAS
entered into senescence, whereas SA-b-gal-positive cells
were not detected when MEF2-ENG was introduced
(Fig. 4G and quantitative analysis in Fig. 4H).
3.5. HDAC4-mediated repression cooperates with
SV40-LT in transforming human fibroblasts
To prove that BJ/TERT cells expressing the nuclear
version of HDAC4 enter senescence as part of a pro-
tective response against an oncogenic dysfunction, it is
imperative to prove that HDAC4 provides some trans-
forming properties. Since anchorage-independent
growth is a clear marker of cellular transformation, we
initially decided to monitor this feature in BJ/TERT/
TP53DN/HDAC4-TM cells that escape senescence.
We also analyzed the effect of the overexpression of
HDAC4-WT, MEF2-ENG and RAS.
Expression of the different transgenes was verified by
immunoblot (Fig. 5A) and soft agar assays were per-
formed to evaluate the anchorage-independent growth.
In none of the engineered cell lines was growth in soft
agar detectable (Fig. 5B). This result indicates that
HDAC4-TM- or MEF2-mediated gene repression can-
not sustain anchorage-independent growth once senes-
cence is suppressed by TP53 mutations.
The SV40 large T antigen (LT) can inactivate two
major tumor suppressor genes, p53 and retinoblastoma
protein (pRb) (Hahn et al., 2002). In several
Fig. 3. The HDAC4-induced senescence is characterized by TP53 activation. (A) TP53 levels in BJ-TERT cells expressing the indicated
transgenes for 8 days. RACK1 was used as loading control. (B) Immunoblot analysis proving the generation of BJ-TERT cells expressing the
DN TP53. Actin was used as loading control. (C) qRT-PCR analysis evaluating the expression of two TP53 target genes in the different BJ-
TERT cell lines as indicated. mRNA levels are relative to BJ-TERT/HYGRO cells. Data are expressed as means  SD, n = 3. **P < 0.01. (D)
Immunoblot analysis evaluating the levels of indicated proteins in BJ-TERT cells after 8 days of 4-OHT treatment. The HDAC4-TM is
expressed as fusion with GFP. Actin was used as loading control. (E) BJ-TERT/TP53DN expressing the indicated transgenes and stained for
SA-b-gal activity. Scale bar: 50 lm. (F) Quantitative analysis of SA-b-gal positivity from experiments described in (F). Data are expressed as
means  SD, n = 4. **P < 0.01.
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experiments LT has proved to cooperate in the trans-
formation of human cells (Hahn et al., 1999). Hence,
we generated BJ-TERT/LT cells (Fig. 5C) to evaluate
oncogenic cooperation with HDAC4-TM, HDAC4-
WT and RAS as a control (Fig. 5D). In contrast to
TP53DN, LT expression suppressed OIS by RAS
(Fig. 5E and quantitative analysis in Fig. 5F). Growth
in soft agar was performed and the appearance of foci
was scored 21 days later. We also evaluated the size
distribution of the colonies (Fig. 5G) using already
published criteria (Cifone and Fidler, 1980). Small
colonies with a 50-lm diameter or less were frequently
observed in RAS- and HDAC4-TM-expressing cells
(Fig. 5H). Rarely, larger colonies with a diameter of
100–150 lm were present. Interestingly, foci of small
dimensions were also observed when TERT/LT/
HDAC4-WT were co-expressed. Analysis of the trans-
formation efficiency confirmed that HDAC4-TM and
RAS showed comparable activities. A much weaker
transforming effect was observed for HDAC4-WT
(Fig. 5I).
To confirm the induction of a transformed pheno-
type we evaluated random motility and invasiveness
using the Matrigel invasion assay. Figure 5J shows
that only HDAC4-TM enhanced random cell motility
but both RAS and HDAC4-TM strongly promoted
invasiveness in TERT/LT human cells (Fig. 5K).
To have a full transformation of human fibroblasts,
both the LT and the SV40 small T antigen (ST) must
be co-expressed with TERT and RAS (Hahn et al.,
Fig. 4. Myocyte enhancer factor transcriptional activity counteracts senescence. (A) Immunoblot analysis evaluating the levels of the
indicated proteins in BJ-TERT cells. MEF2D and MEF2-ENG contain a Flag epitope. Actin was used as loading control. (B) Quantitative
analysis of SA-b-gal positivity in BJ-TERT cells expressing the indicated transgenes. (C) Immunoblot analysis of MEF2D, HDAC4 and
CDKN1A levels in BJ-TERT cells expressing the control shRNA or a shRNA against MEF2D. shRNA was delivered by lentiviral infection.
Actin was used as loading control. (D) Analysis of DNA synthesis, as scored after BrdU staining in BJ-TERT cells expressing the two
shRNA. Data are expressed as means  SD, n = 3. *P < 0.05. (E) BJ-TERT expressing the indicated shRNA were stained for SA-b-gal
activity. Scale bar: 50 lm. (F) Quantitative analysis of SA-b-gal positivity from experiments described in (E). Data are expressed as means 
SD, n = 4. **P < 0.01. (G) BJ-TERT/TP53 expressing the indicated transgene were stained for SA-b-gal activity. Scale bar: 50 lm. (H)
Quantitative analysis of SA-b-gal positivity from experiments described in (G). Data are expressed as means  SD, n = 4. ***P < 0.005.
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Fig. 5. The HDAC4-TM cooperates with SV40 LT in sustaining a transformed phenotype. (A) Immunoblot analysis of indicated proteins as
expressed in BJ-TERT/TP53DN cells infected with retrovirus encoding the indicated genes. HDAC4 was expressed as fusion with GFP and
the recombinant proteins detected with an anti-GFP antibody. Actin was used as loading control. (B) Growth in soft agar of the BJ-TERT/
TP53 cells expressing the indicated transgene. After staining with MTT, foci with diameter > 50 lm were counted. Data are expressed as
means  SD, n = 3. Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005. (C) Immunoblot analysis of indicated proteins as expressed in BJ-
TERT cells infected with retrovirus encoding the indicated genes. Actin was used as loading control. (D) Immunoblot analysis of indicated
proteins as expressed in BJ-TERT/LT cells infected with retrovirus encoding the indicated genes. HDAC4 was expressed as fusion with GFP
and the recombinant proteins detected with an anti-GFP antibody Actin was used as loading control. (E) BJ-TERT/LT cells expressing the
indicated transgenes were stained for SA-b-gal activity. Scale bar: 50 lm. (F) Quantitative analysis of SA-b-gal positivity from experiments
described in (E). Data are expressed as means  SD, n = 3. Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005. (G) Representative images
of MMT positive soft agar foci of BJ-TERT/LT cells expressing HDAC4-TM or RAS. Scale bars are indicated. (H) Quantitative analysis of soft
agar foci of BJ-TERT/LT cells expressing the indicated transgenes grouped for foci dimensions related to (G). Data are expressed as
means  SD, n = 4. Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005. (I) Soft agar transformation efficiency represents the total number
of foci generated by BJ-TERT/LT cells expressing the indicated transgenes, divided by the total number of seeded cells. Data are expressed
as means  SD, n = 4. ***P < 0.005. (J) Motility properties of BJ-TERT/LT cells expressing RAS, HDAC4-TM or HYGRO as control. Data
are expressed as means  SD, n = 3. ***P < 0.005. (K) Invasive properties, as measured by Matrigel invasion assay of BJ-TERT/LT cells
expressing RAS, HDAC4-TM or Hygro as control. Data are expressed as means  SD, n = 3. *P < 0.05, ***P < 0.005.
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Fig. 6. The HDAC4-TM cooperates with SV40 LT in sustaining a transformed phenotype. (A) Immunoblot analysis of indicated proteins as
expressed in BJ-TERT/LT/ST cells infected with retrovirus encoding the indicated genes. HDAC4 was expressed as fusion with GFP and the
recombinant proteins detected with an anti-GFP antibody. Actin was used as loading control. (B) Representative images of MMT-positive
soft agar foci of BJ-TERT/LT/ST cells expressing HDAC4-TM or RAS. Scale bars are indicated. (C) Quantitative analysis of soft agar foci of
BJ-TERT/LT/ST cells expressing the indicated transgenes grouped for foci dimensions related to Fig. 6B. Data are expressed as
means  SD, n = 4. Student t-test: *P < 0.05, **P < 0.01, ***P < 0.005. (D) Soft agar transformation efficiency represents the total
number of foci generated by BJ-TERT/LT/ST cells expressing the indicated transgenes divided by the total number of seeded cells. Data are
expressed as means  SD, n = 4. **P < 0.01, ***P < 0.005. (E) Percentage of invasive soft agar foci. Foci were scored for the presence of
cells showing extensive growth in the surrounding agar. The means and the 1st and 3rd quartiles are indicated. n = 19 (HDAC4-TM) and
n = 15 (RAS). ***P < 0.005. (F) Motility properties of BJ-TERT/LT/ST cells expressing RAS, HDAC4-TM or Hygro as control. Data are
expressed as means  SD, n = 3. Student t-test: **P < 0.01. (G) Invasive properties, as measured by Matrigel invasion assay of BJ-TERT/
LT/ST cells expressing RAS, HDAC4-TM or Hygro as control. Data are expressed as means  SD, n = 3. **P < 0.01. (H) Confocal images
representing the equatorial section of BJ-TERT/LT/ST cells expressing RAS or HDAC4-TM grown in Matrigel plugs. Nuclei were visualized
using Hoechst 33342 and actin filaments with phalloidin-Alexa 546.
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2002). Hence, we generated human fibroblasts express-
ing the combination of TERT/LT/ST together with
HDAC4-WT, HDAC4-TM or RAS as a positive con-
trol of transformation. Immunoblot analysis verified
the expression of the different transgenes (Fig. 6A).
Next, soft agar assay was performed and after
21 days, colonies were stained with MTT and foci
were counted and grouped for dimensions as exempli-
fied (Fig. 6B). Quantitative analysis proved that the
expression of the ST increased the number of foci and
particularly their dimensions (Fig. 6C) as well as the
transformation efficiency (compare Fig. 6D with
Fig. 5I). Interestingly, cells expressing HDAC4-TM
frequently show extensive invasion and some branch-
ing into the agar (Fig. 6B). Quantitative analysis con-
firmed the invasive properties of foci generated by
HDAC4-TM (Fig. 6E). Here, again, growth in soft
agar was also observed when HDAC4-WT was
expressed, although with reduced efficiency compared
with HDAC4-TM (Fig. 6C,D).
To confirm the invasive properties of TERT/LT/ST/
HDAC4-TM cells we performed the Matrigel invasion
assay. Random cell motility and invasion were mea-
sured (Fig. 6F,G). These experiments confirmed the
strong invasive behavior of HDAC4-TM-expressing
cells.
Finally, we analyzed TERT/LT/ST cells expressing
HYGRO, RAS and HDAC4-TM in three-dimensional
Matrigel plugs. Only cells expressing RAS or HDAC4-
TM exhibited robust growth and invasion into the
matrix (Fig. 6H).
3.6. Common and specific transcriptomic
adaptations characterize RAS and HDAC4-TM
transformed cells
To gain insight into the molecular mechanisms responsi-
ble for the RAS- and HDAC4-TM- mediated oncogenic
transformation, we performed gene expression profile
studies. The transcriptomes of TERT/LT/ST/HYGRO,
TERT/LT/ST/RAS and TERT/LT/ST/HDAC4-TM
were compared. DEGs were analyzed relative to TERT/
LT/ST/HYGRO cells. Figure 7A shows that RAS and
HDAC4-TM influence the expression of a comparable
number of genes (respectively 892 and 920). In both
cases, the number of repressed genes is more than the
double that of the induced ones. Moreover, HDAC4-
TM and RAS have a larger pool (15.5%, n = 156 genes)
of all the repressed genes in common, in contrast to
6.5% (n = 40) of up-regulated genes. Since HDAC4 is a
transcriptional repressor, we focused our analysis on the
repressed genes. The 156 commonly repressed genes
turned out to be highly enriched for elements of the
interferon (IFN) pathways (Fig. 7B). In addition and in
agreement with the transformed state of these cells, a
subset of the commonly silenced genes belong to the
category of genes repressed by serum/growth
factors (Fig. 7B). Next, we evaluated RAS- and
HDAC4-TM-specific repressive signatures. IFN and, in
general, inflammatory signatures were prevalent among
genes (n = 400) specifically repressed by RAS (Fig. 7C).
In contrast, genes that are specifically repressed by
HDAC4-TM are involved in more heterogeneous regu-
lative processes, including the epithelial-mesenchymal
transition, the hypoxia response and differentiation/
morphogenesis (Fig. 7D). The high number of genes
regulating cell adhesion and migration, as disclosed by
the Gene Ontology analysis, could explain the peculiar
phenotype of the soft agar colonies generated by TERT/
LT/ST/HDAC4-TM cells (Fig. 6).
Finally, the comparison of the transcriptomic pro-
files indicated that the transformation phenotype eli-
cited by HDAC4-TM in TERT/LT/ST cells resembles
adaptations in gene expression previously described in
other models of human fibroblast transformation
(Fig. 7E).
4. Discussion
In this manuscript we used human fibroblasts to evalu-
ate the oncogenic cooperative properties of HDAC4.
The transforming potential of class IIa HDACs has
been shown in different murine models (Di Giorgio
et al., 2013; Gil et al., 2016; Lei et al., 2017; Peruzzo
et al., 2016; Rad et al., 2010). However, since there are
substantial interspecies differences in the biology of cell
transformation (Boehm et al., 2005), we decided to ver-
ify the oncogenic properties of HDAC4 in human cells.
The combined expression of HDAC4-TM with the
viral oncogene LT and much more strongly with LT
and ST viral oncogenes can sustain growth in soft agar,
similarly to RAS oncogene. Although at reduced levels,
HDAC4-WT can also promote anchorage-independent
growth when co-expressed with LT and ST.
The ability of LT to cooperate with HDAC4
strongly indicates that inactivation of the pRb and
TP53 tumor suppressor pathways is required to
unleash the HDAC4-transforming potential. However,
in the absence of ST, the growth is not robust and foci
are less frequently observed and of small size. This
behavior was previously reported in the case of RAS
(Hahn et al., 2002).
ST is required to increase dramatically the anchor-
age-independent growth of both HDAC4 and RAS.
ST-transforming activities rely on the binding and
inhibition of some isoforms of the serine-threonine
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phosphatase, PP2A (Hahn et al., 2002). PP2A can
dephosphorylate and regulate several targets, thus
making it difficult to hypothesize which pathway could
synergize with HDAC4. Recently, it has been shown
that the PAK1-YAP axis can mediate ST-transforming
activity (Nguyen et al., 2014). Interestingly, a
Fig. 7. Gene expression profiles of RAS and HDAC4-TM transformed human fibroblasts. (A) Pie-chart indicating the number of genes
significantly up- and down-regulated in TERT/LT/ST/RAS and TERT/LT/ST/HDAC4-TM cells compared with TERT/LT/ST/HYGRO cells. (B)
GSEA for the 156 genes commonly repressed by RAS and HDAC4-TM using the hallmark and the GO/biological process MSigDB gene
sets. (C) GSEA for the 400 genes specifically repressed by RAS using the hallmark and the curated (CPG) MSigDB gene sets. (D) GSEA for
the 450 genes specifically repressed by HDAC4-TM using the hallmark and the GO/biological process MSigDB gene sets. (E) GSEA plots
showing significant enrichment for HDAC4-regulated genes in a BJ transformation model (GSE43010), considering both HDAC4-positively
regulated genes (left) and HDAC4-repressed genes (right).
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contribution of HDAC4 in mediating YAP-repressive
activity has been reported (Wang et al., 2014).
Transcriptomic analysis has revealed that HDAC4-
TM and RAS trigger the transformation processes via
both common and peculiar adaptive responses. Repres-
sion of genes marking the IFN responses was commonly
found in RAS- and HDAC4-TM-transformed cells.
IFN and inflammatory signaling were highly enriched
also among genes specifically repressed by RAS.
Although it is well known that RAS and its downstream
elements suppress the IFN-induced antiviral responses
and favor virus spreading (Battcock et al., 2006; Chris-
tian et al., 2009; Noser et al., 2007), how this repressive
wave could impact on the in vitro transformation pro-
cess is less clear (Christian et al., 2012). Gene signatures
specifically influenced by HDAC4-TM are more hetero-
geneous and involve adaptation to hypoxia, adhesion,
motility and differentiation processes. It is possible that
RAS more potently suppresses the IFN responses
compared with HDAC4-TM, which instead represses
additional pathways.
The ability of HDAC4-TM to regulate genes
involved in adhesion and motility was confirmed in the
morphological analysis of soft agar foci as well as in
the results obtained with Matrigel invasion and
evasion assays. These results indicate that HDAC4-
expressing cells exhibit a strong invasive phenotype,
further supported by previous studies on the invasive,
migrating and metastatic activities of class IIa HDACs
(Cao et al., 2017; Cernotta et al., 2011; Di Giorgio
et al., 2013; Fabian et al., 2016; Mottet et al., 2007).
Normal cells in response to oncogenic signals enter
into senescence, a state of irreversible/permanent
growth arrest that prevents cells from undergoing fur-
ther cell divisions, defined as OIS (Serrano et al., 1997).
Activation of OIS depends on the pRB and/or TP53
tumor suppressor pathways (Serrano et al., 1997). We
have proved that HDAC4-TM, in TERT-immortalized
human fibroblasts, can activate senescence. This senes-
cent response can be also triggered by other class IIa
HDACs such as HDAC7, when localized into the
nucleus (Supporting Information Fig. S1). Since the
expression of HDAC4-TM in the opportune genetic
environment (LT/ST co-expression) can transform cells,
and since the senescent response is p53-dependent, we
can define senescence triggered by HDAC4-TM as OIS.
However, OIS induced by RAS cannot be reversed by
simply blocking TP53 activity, but requires the suppres-
sion of pRB, possibly through the CDK inhibitor p16
(Serrano et al., 1997). The difference between HDAC4-
TM and RAS can be appreciated also at the earliest
stages of their induction. RAS triggers hyperprolifera-
tion and S-phase-associated DNA damage response
(DDR). The oncogene-dependent increase in prolifera-
tion leads to accumulation of incomplete replication
intermediates, resulting in DNA damage and activation
of the DDR (Di Micco et al., 2006).
In contrast, HDAC4-TM triggers suddenly growth
arrest, senescence and SASP, which could be caused
by the rapid activation of TP53. The absence of the
hyperproliferative response correlates with the failure
to trigger H3K27 global demethylation, as observed in
RAS-expressing cells.
4.1. How can HDAC4-TM trigger TP53
stabilization and senescence?
Induction of DNA damage, marked by cH2AX posi-
tivity, was observed. In contrast to RAS, the number
of cH2AX spots per cell was reduced in HDAC4-TM
cells. Hence, the induction of DNA damage and TP53
activation seems to involve different pathways com-
pared with the replication stress induced by RAS. Pre-
vious reports have described correlations between
HDAC4 and the DNA damage response, and also
with TP53 regulation (Cadot et al., 2009; Marampon
et al., 2017). Unfortunately, these preliminary observa-
tions have not led to further studies and currently the
correlations between class IIa HDACs and the DNA
damage response remain unknown.
Although RAS-induced OIS is among the foremost
pathways, alternative OIS pathways exist. PI3K/AKT-
induced senescence is characterized by TP53 and
CDKN1A induction in the absence of overt DNA
damage. mTORC1-dependent regulation of TP53
translation and stabilization of TP53 protein, as a
result of MDM2 nucleolar localization and inactiva-
tion, is the mechanism activated in this senescent
response (Astle et al., 2012; Kennedy et al., 2011).
Importantly, similarly to HDAC4, AKT promotes a
rapid proliferative arrest in the absence of hyperprolif-
eration (Astle et al., 2012; Kennedy et al., 2011).
Interestingly, in certain cancer types, particularly in
leiomyosarcomas, class IIa HDACs and PI3K/AKT
can regulate common genetic programs that are under
the influence of MEF2 TFs. Class IIa HDAC binds
MEF2 on target promoters and favors the establish-
ment of a closed chromatin configuration (Di Giorgio
et al., 2017). In contrast, PI3K/AKT can trigger
polyubiquitylation and degradation of certain MEF2
isoforms (Di Giorgio et al., 2015). As MEF2s are pos-
sible common targets of these pathways, it is impor-
tant to underline that the repression of MEF2 TFs is
required for the OIS response triggered by HDAC4
and that the knock-down of MEF2D is sufficient to
trigger senescence.
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5. Conclusions
Our results provide further evidence concerning the
contribution, as cooperating oncogenes, of class IIa
HDACs in human cancer. This finding is encouraging
for further investigations aimed at discovering and
evaluating inhibitors of these epigenetic regulators as
anticancer drugs.
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